U 62840

Subscribe to Selected New Research on U 62840

4 relevant articles (2 outcomes, 2 trials/studies) found for this Bio-Agent

Description: stereoisomeric benzindene prostaglandin analog; structure given in first source

Also Known As:

15 AU81; 15AU81; U-62,840; Acetic acid, ((2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-(3-hydroxyoctyl)-1H-benz(f)inden-5-yl)oxy)-, (1R-(1alpha(S*),2beta,3aalpha,9aalpha))-

Relationship Network

Bio-Agent Context: Research Results

Lipids: 13315

Fatty Acids: 4660

Unsaturated Fatty Acids: 2221

Eicosanoids: 1153

Prostaglandins: 6156

Synthetic Prostaglandins: 156

U 62840: 4

Biological Factors: 868

Inflammation Mediators: 485

Synthetic Prostaglandins: 156

U 62840: 4

Related Diseases

1.	Heart Failure 08/01/1991 - "The purpose of this study was to evaluate the cardiovascular effects of 15AU81 in anesthetized dogs in order to assess this agent's potential for clinical study in the treatment of congestive heart failure" 01/19/1995 - "The most common adverse event to limit dose-ranging was headache, which occurred at a mean maximum tolerated dose of 36 +/- 15 ng/kg/min. Administration of 15AU81 was associated with significant acute hemodynamic improvement in patients with severe heart failure.(ABSTRACT TRUNCATED AT 250 WORDS)" 08/01/1991 - "The hemodynamic profile of 15AU81 suggests that, through its rapid onset and ability to reduce loading conditions of the right and left ventricles and its chemical stability over natural prostacyclin, this prostacyclin analog may have utility in the management of chronic congestive heart failure." 01/19/1995 - "This multicenter, open-label study provides the first assessment of the safety and acute hemodynamic effects of a short-term infusion of 15AU81, a chemically stable analog of prostacyclin, in patients with New York Heart Association class III or IV heart failure" 01/19/1995 - "Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure." Get all the results and reference details, order at left...
2.	Headache (Headaches) 01/19/1995 - "The most common adverse event to limit dose-ranging was headache, which occurred at a mean maximum tolerated dose of 36 +/- 15 ng/kg/min. Administration of 15AU81 was associated with significant acute hemodynamic improvement in patients with severe heart failure.(ABSTRACT TRUNCATED AT 250 WORDS)" Get all the results and reference details, order at left...
2 Diseases and 4 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
1 Drugs and Important Bio-Agents and 4 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>